scholarly journals OP0107 CLINICAL EFFICACY OF ROMOSOZUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS FOR 12 MONTHS

2021 ◽  
Vol 80 (Suppl 1) ◽  
pp. 59.1-60
Author(s):  
Y. Kanayama ◽  
R. Sugimoto
Keyword(s):  
Rheumatoid Arthritis ◽  
Bone Mineral Density ◽  
Bone Turnover ◽  
Bone Mineral ◽  
Clinical Efficacy ◽  
Vertebral Fractures ◽  
Mineral Density ◽  
T Score ◽  
Tracp 5B ◽  
Turnover Markers

Background:Romosozumab (ROMO), a monoclonal antibody that binds sclerostin, increases bone formation and decreases bone resorption. And although it is a novel therapeutic agent for osteoporosis, which has shown high effects of increasing bone density and inhibiting fragile fracture in overseas clinical trials. However the clinical efficacy for rheumatoid arthritis complicated with osteoporosis (RA-OP) is unknown.Objectives:To evaluate the clinical efficacy of ROMO in patients with RA-OP for 12 months.Methods:RA patients diagnosed according to the 2010 ACR/EULAR criteria. All patients met at least one of the following criteria were eligible; a bone mineral density T score of -2.5 or less at the lumber spine or total hip and either one or more moderate or severe vertebral fractures or two or more mild vertebral fractures. All patients were initiated ROMO from between March and December, 2019. The total number of patients was 13 cases. The ROMO dose was 210mg at once every 1 months. In all cases native or activated vitamin D has been used. We reviewed the results for 12 months about the increase and decrease of bone mineral density (BMD) of lumbar spine(LS) and total hip(TH) by DEXA and bone turnover markers, intact n-terminal propeptide type I procollagen(PINP) and tartrate-resistant acid phopshatate form 5b(TRACP-5b).Results:The gender was all female. The mean age was 73.2 ± 7.6; disease duration was 20.5 ± 16.9 years; the body mass index was 19.7 ± 3.0 and the FRAX was 40.5 ± 16.2. Clinical findings related to RA-OP at baseline were as follows; CRP 1.29 ± 1.66; DAS-CRP 3.43 ± 0.96; HAQ 1.59 ± 0.97 and, bone turnover markers and bone mineral density at baseline were as follows; P1NP 58.1 ± 33.5; TRACP-5b 438 ± 216; LS-BMD and T-score 0.81 ± 0.15 g/cm2 and -2.63 ± 1.05 and TH-BMD 0.54 ± 0.08 g/cm2 and -3.22 ± 0.64 g/cm2. The rate of increased P1NP from baseline to 1, 3, 6 and 12 months were each 114.3 ± 90.6% at 1 month, 131.6 ± 134.3% at 3 month, 122.6 ± 174.3% at 6 month and 80.4 ± 181.6% at 12 month and decreased TRAC-5b were -10.7 ± 20.8% at 1 month, 7.9 ± 36.9% at 3 month, 25.5 ± 64.6% at 6 month and 32.5 ± 77.0% at 12 month. The rate of increased LS-BMD from baseline to 6 and 12 months were 8.6 ± 8.0%, 12.5 ± 11.1% and TH-BMD were 4.3 ± 5.0%, 6.8 ± 6.9% (Fig. 1, 2).Conclusion:Clinical efficacy of ROMO for RA-OP was extremely effective and has the high potential to be an important option in the treatment of RA-OP.References:Disclosure of Interests:None declared

scholarly journals SAT0454 EARLY CLINICAL EFFICACY OF ROMOSOZUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS AND PRIMARY OSTEOPOROSIS

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 1184.1-1185
Author(s):  
Y. Kanayama ◽  
R. Sugimoto
Keyword(s):  
Rheumatoid Arthritis ◽  
Bone Mineral Density ◽  
Bone Turnover ◽  
Bone Mineral ◽  
Clinical Efficacy ◽  
Primary Osteoporosis ◽  
Mineral Density ◽  
T Score ◽  
Tracp 5B ◽  
Turnover Markers

Background:Romosozumab (ROM), a monoclonal antibody that binds sclerostin, increases bone formation and decreases bone resorption. And although it is a novel therapeutic agent for osteoporosis, which has shown high effects of increasing bone density and inhibiting fragile fracture in overseas clinical trials. However the clinical efficacy in daily clinical practice is unknown.Objectives:To evaluate the early clinical efficacy of ROM in patients with osteoporosis between rheumatoid arthritis (RA-OP) and primary osteoporosis (P-OP) for 6 months.Methods:RA patients diagnosed according to the 2010 ACR/EULAR criteria. RA-OP and P-OP patients met at least one of the following criteria were eligible; a bone mineral density T score of -2,5 or less at the lumber spine or total hip and either one or more moderate or severe vertebral fractures or two or more mild vertebral fractures. All patients were initiated ROM from between March and June, 2019. The total number of patients was 15 cases, including 8 RA-OP and 7 P-OP. All patients received continuous ROM therapy more than 6 months. The DMB dose was 210mg at once every 1 months. In all cases native or activated vitamin D has been used. We reviewed the results for 6 months about the increase and decrease of bone mineral density (BMD) of lumbar spine(LS) and total hip(TH) by DEXA and bone turnover markers, intact n-terminal propeptide type I procollagen(PINP) and tartrate-resistant acid phopshatate form 5b(TRACP-5b).Results:The gender was all female. The mean age was 71.8 ± 8.7; disease duration of RA-OP patients was 23.0 ± 15.1 years; the body mass index was 19.9 ± 3.2 and the FRAX was 32.5 ± 14.9. Clinical findings related to RA-OP at baseline were as follows; CRP 0.97 ± 0.77; DAS-CRP 3.22 ± 0.41; HAQ 1.41 ± 0.94 in RA-OP patients and in the all patients, bone turnover markers and bone mineral density at baseline were as follows; P1NP 72.2 ± 39.8; TRACP-5b 539 ± 212; LS-BMD and T-score 0.80 ± 0.20 g/cm2and -2.75 ± 1.36 and TH-BMD 0.55 ± 0.07 g/cm2and -3.18 ± 0.55 g/cm2. The rate of increased P1NP from baseline to 1, 3 and 6 months were each -96.8 ± 80.8% at 1 month, 106.8 ± 115.6% at 3 month and 90.7 ± 115.7% at 6 month and decreased TRAC-5b were -20.4 ± 20.6% at 1 month, -80.8 ± 19.6% at 3 month and -1.8 ± 50.8% at 6 month. The rate of increased LS-BMD from baseline to 6 months were 11.0 ± 8.0% and TH-BMD were 5.3 ± 3.8% (Fig. 1, 2).Conclusion:Early clinical efficacy of ROM for RA-OP and P-OP was extremely effective and has the high potential to be an important option in the treatment of osteoporosis.Disclosure of Interests:None declared

Short-Term Effects of TNF Inhibitors on Bone Turnover Markers and Bone Mineral Density in Rheumatoid Arthritis

2016 ◽  
Vol 98 (6) ◽  
pp. 580-585 ◽  
Author(s):  
Giovanni Orsolini ◽  
Giovanni Adami ◽  
Silvano Adami ◽  
Ombretta Viapiana ◽  
Luca Idolazzi ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Bone Mineral Density ◽  
Bone Turnover ◽  
Bone Mineral ◽  
Bone Turnover Markers ◽  
Tnf Inhibitors ◽  
Mineral Density ◽  
Short Term ◽  
Turnover Markers ◽  
Short Term Effects

scholarly journals Reference Values for Bone Mineral Density and Bone Turnover Markers in the General Elderly Population: A Japanese Cohort Survey Randomly Sampled From A Basic Resident Registry

2020 ◽  
Author(s):  
Ryosuke Tokida ◽  
Masashi Uehara ◽  
Yukio Nakamura ◽  
Noriko Sakai ◽  
Shota Ikegami ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Bone Turnover ◽  
Bone Mineral ◽  
Bone Turnover Markers ◽  
Elderly Population ◽  
Bone Markers ◽  
Mineral Density ◽  
Tracp 5B ◽  
Turnover Markers ◽  
General Elderly Population

Abstract The aim of this study was to provide definitive reference values for bone mineral density (BMD) and bone turnover markers in the general elderly population. Registered citizens of 50 to 89 years old were targeted for this survey. After random sampling from the resident registry of Obuse town, we established eight groups based on age (50s, 60s, 70s, and 80s) and gender. A total of 411 people were enrolled. We used a dual-energy x-ray absorptiometry device to measure and evaluate BMD. The bone formation marker bone alkaline phosphatase (BAP) was measured as a bone turnover marker. Bone resorption markers, including pentosidine, urinary total deoxypyridinoline, urinary type I collagen N-telopeptide, tartrate-resistant acid phosphatase 5b (TRACP-5b), 25-hydroxyvitamin D, and whole PTH were also measured as bone turnover markers.Sixty-three people (15.3%) were diagnosed as OP. In women, BMD decreased with age. On the other hand, there was no characteristic change with age in men. As for bone markers, 25(OH)D, whole parathyroid hormone, and BAP showed no characteristics associated with gender and aging. In terms of the association between low BMD and bone markers, there was a significant association between low BMD and TRACP-5b in females.In conclusions, BMD decreased with age in women. However, there was no decline with age in men. All bone metabolism markers showed no significant characteristics associated with age or gender, except for a significant association between low BMD and TRACP-5b in females. TRACP-5b was a potentially useful marker for the detection of low BMD.

scholarly journals Effects of denosumab on bone mineral density and bone turnover markers in rheumatoid arthritis patients switching from bisphosphonates

2019 ◽  
Vol 6 (1) ◽  
Author(s):  
Tetsuya Kaneko ◽  
Koichi Okamura ◽  
Yukio Yonemoto ◽  
Chisa Okura ◽  
Takahito Suto ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Bone Mineral Density ◽  
Bone Turnover ◽  
Bone Mineral ◽  
Bone Turnover Markers ◽  
Mineral Density ◽  
Naive Group ◽  
Treatment Naïve ◽  
Turnover Markers ◽  
Switch Group

Abstract Background To compare the efficacy of 12-month denosumab treatment on bone mineral density (BMD) and bone turnover markers (BTMs) between treatment-naïve osteoporosis patients with rheumatoid arthritis (RA) and those with previous bisphosphonate (BP) therapy. Methods A total of 36 RA patients with osteoporosis completed 12-month follow-up. Twenty-five patients were osteoporotic treatment-naïve (naïve group), and 11 patients were previously treated with BPs (switch group) (average 7.9 years). BMD and BTMs were measured before and 6 and 12 months after treatment. Results BTM levels were higher in the naïve group at baseline. However, the same level of suppression was achieved at 6 months in both groups. Spine BMD increased significantly in both groups. There was no significant difference in the mean percent changes of BMD of the spine (naïve group: 6.8 ± 0.8, switch group: 5.1 ± 1.5), femoral neck (2.9 ± 1.4, 2.9 ± 1.3), and total hip (1.7 ± 0.9, 1.4 ± 1.1) between these two groups at 12 months. Conclusions The effects of denosumab on BMD and BTMs of the switch group after long-term BP treatment are comparable to those of the naïve group in RA patients. Thus, switching BPs to denosumab is one of the useful options to treat osteoporosis with RA.

Bone mineral density and bone turnover markers in patients with thyroid cancer and L-T4 suppressive therapy after 25 years of follow-up

2014 ◽  
Author(s):  
Mingo Dominguez Maria Luisa de ◽  
Sonsoles Guadalix Iglesias ◽  
Maria Begona Lopez Alvarez ◽  
Guillermo Martinez Diaz-Guerra ◽  
Federico Hawkins Carranza
Keyword(s):  
Bone Mineral Density ◽  
Thyroid Cancer ◽  
Bone Turnover ◽  
Bone Mineral ◽  
Bone Turnover Markers ◽  
Suppressive Therapy ◽  
Mineral Density ◽  
Turnover Markers
Sign in / Sign up

Export Citation Format

Share Document